1. Name Of The Medicinal Product
Zarzio 30 MU/0.5 ml solution for injection or infusion in pre-filled syringe
2. Qualitative And Quantitative Composition
Each ml of solution contains 60 million units (MU) [equivalent to 600 micrograms (μg)] filgrastim*.
Each pre-filled syringe contains 30 MU (equivalent to 300 μg) filgrastim in 0.5 ml.
* recombinant methionylated human granulocyte-colony stimulating factor (G-CSF) produced in E. coli by recombinant DNA technology.
Excipient: Each ml of solution contains 50 mg sorbitol (E420).
For a full list of excipients, see section 6.1.
3. Pharmaceutical Form
Solution for injection or infusion in pre-filled syringe
Clear, colourless to slightly yellowish solution.
4. Clinical Particulars
4.1 Therapeutic Indications
- Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.
The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy.
- Mobilisation of peripheral blood progenitor cells (PBPC).
- In children and adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of 9/l, and a history of severe or recurrent infections, long term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.
- Treatment of persistent neutropenia (ANC 9/l) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other therapeutic options are inappropriate.
4.2 Posology And Method Of Administration
Filgrastim therapy should only be given in collaboration with an oncology centre which has experience in granulocyte-colony stimulating factor (G-CSF) treatment and haematology and has the necessary diagnostic facilities.
The mobilisation and apheresis procedures should be performed in collaboration with an oncology-haematology centre with acceptable experience in this field and where the monitoring of haematopoietic progenitor cells can be correctly performed.
Zarzio is available in strengths of 30 MU/0.5 ml and 48 MU/0.5 ml.
Established cytotoxic chemotherapy
The recommended dose of filgrastim is 0.5 MU/kg/day (5 μg/kg/day). The first dose of filgrastim should not be administered less than 24 hours following cytotoxic chemotherapy.
Daily dosing with filgrastim should continue until the expected neutrophil nadir is passed and the neutrophil count has recovered to the normal range. Following established chemotherapy for solid tumours, lymphomas, and lymphoid leukaemias, it is expected that the duration of treatment required to fulfil these criteria will be up to 14 days. Following induction and consolidation treatment for acute myeloid leukaemia the duration of treatment may be substantially longer (up to 38 days) depending on the type, dose and schedule of cytotoxic chemotherapy used.
In patients receiving cytotoxic chemotherapy, a transient increase in neutrophil counts is typically seen 1 - 2 days after initiation of filgrastim therapy. However, for a sustained therapeutic response, filgrastim therapy should not be discontinued before the expected nadir has passed and the neutrophil count has recovered to the normal range. Premature discontinuation of filgrastim therapy, prior to the time of the expected neutrophil nadir, is not recommended.
Patients treated with myeloablative therapy followed by bone marrow transplantation
The recommended starting dose of filgrastim is 1.0 MU/kg/day (10 μg/kg/day). The first dose of filgrastim should not be administered less than 24 hours following cytotoxic chemotherapy and within 24 hours of bone marrow infusion.
Dose adjustments: Once the neutrophil nadir has been passed, the daily dose of filgrastim should be titrated against the neutrophil response as follows:
Absolute neutrophil count
|
Filgrastim dose adjustment
|
ANC > 1.0 x 109/l for 3 consecutive days
|
Reduce to 0.5 MU/kg/day (5 μg/kg/day)
|
Then, if ANC remains > 1.0 x 109/l for 3 more consecutive days
|
Discontinue filgrastim
|
If the ANC decreases to < 1.0 x 109/l during the treatment period, the dose of filgrastim should be re-escalated according to the above steps
|
|
Mobilisation of PBPC
Patients undergoing myelosuppressive or myeloablative therapy followed by autologous PBPC transplantation
The recommended dose of filgrastim for PBPC mobilisation when used alone is 1.0 MU/kg/day (10 μg/kg/day) for 5 - 7 consecutive days. Timing of leukapheresis: 1 or 2 leukaphereses on days 5 and 6 are often sufficient. In other circumstances, additional leukaphereses may be necessary. Filgrastim dosing should be maintained until the last leukapheresis.
The recommended dose of filgrastim for PBPC mobilisation after myelosuppressive chemotherapy is 0.5 MU/kg/day (5 μg/kg/day) given daily from the first day after completion of chemotherapy until the expected neutrophil nadir is passed and the neutrophil count has recovered to the normal range. Leukapheresis should be performed during the period when the ANC rises from < 0.5 x 109/l to > 5.0 x 109/l. For patients who have not had extensive chemotherapy, one leukapheresis is often sufficient. In other circumstances, additional leukaphereses are recommended.
There are no prospectively randomised comparisons of the two recommended mobilisation methods (filgrastim alone or in combination with myelosuppressive chemotherapy) within the same patient population. The degree of variation between individual patients and between laboratory assays of CD34+ cells means that direct comparison between different studies is difficult. It is therefore difficult to recommend an optimum method. The choice of mobilisation method should be considered in relation to the overall objectives of treatment for an individual patient.
Normal donors prior to allogeneic PBPC transplantation
For PBPC mobilisation in normal donors prior to allogeneic PBPC transplantation, filgrastim should be administered at 1.0 MU/kg/day (10 μg/kg/day) for 4 - 5 consecutive days. Leukapheresis should be started at day 5 and continued until day 6 if needed in order to collect 4 x 106 CD34+ cells/kg recipient bodyweight (BW).
Severe chronic neutropenia (SCN)
Congenital neutropenia
The recommended starting dose is 1.2 MU/kg/day (12 μg/kg/day) as a single dose or in divided doses.
Idiopathic or cyclic neutropenia
The recommended starting dose is 0.5 MU/kg/day (5 μg/kg/day) as a single dose or in divided doses.
Dose adjustments
Filgrastim should be administered daily until the neutrophil count has reached and can be maintained at more than 1.5 x 109/l. When the response has been obtained, the minimal effective dose to maintain this level should be established. Long-term daily administration is required to maintain an adequate neutrophil count.
After 1 - 2 weeks of therapy, the initial dose may be doubled or halved depending upon the patient's response. Subsequently the dose may be individually adjusted every 1 - 2 weeks to maintain the average neutrophil count between 1.5 x 109/l and 10 x 109/l. A faster schedule of dose escalation may be considered in patients presenting with severe infections. In clinical studies, 97% of patients who responded had a complete response at doses of
HIV infection
Reversal of neutropenia
The recommended starting dose of filgrastim is 0.1 MU/kg/day (1 μg/kg/day) given daily with titration up to a maximum of 0.4 MU/kg/day (4 μg/kg/day) until a normal neutrophil count is reached and can be maintained (ANC > 2.0 x 109/l). In clinical studies, > 90% of patients responded at these doses, achieving reversal of neutropenia in a median of 2 days.
In a small number of patients (< 10%), doses up to 1.0 MU/kg/day (10 μg/kg/day) were required to achieve reversal of neutropenia.
Maintenance of normal neutrophil counts
When reversal of neutropenia has been achieved, the minimal effective dose to maintain a normal neutrophil count should be established. Initial dose adjustment to alternate day dosing with 30 MU/day (300 μg/day) is recommended. Further dose adjustment may be necessary, as determined by the patient's ANC, to maintain the neutrophil count at > 2.0 x 109/l. In clinical studies, dosing with 30 MU/day (300 μg/day) on 1 - 7 days per week was required to maintain the ANC > 2.0 x 109/l, with the median dose frequency being 3 days per week. Long-term administration may be required to maintain the ANC > 2.0 x 109/l.
Special populations
Patients with renal/hepatic impairment
Studies of filgrastim in patients with severe impairment of renal or hepatic function demonstrate that it exhibits a similar pharmacokinetic and pharmacodynamic profile to that seen in normal individuals. Dose adjustment is not required in these circumstances.
Paediatric patients in the SCN and cancer settings
In clinical studies 65% of patients treated for SCN were younger than 18 years. For this age-group, which mostly includes patients with congenital neutropenia, efficacy was proven. There were no differences in the safety profiles for paediatric patients treated for SCN in comparison to adults.
Data from clinical studies in paediatric patients indicate that the safety and efficacy of filgrastim are similar in both adults and children receiving cytotoxic chemotherapy.
The dosage recommendations in paediatric patients are the same as those in adults receiving myelosuppressive cytotoxic chemotherapy.
Elderly patients
In clinical investigations with filgrastim a small number of elderly patients was included. No specific studies have been performed for this patient population. Therefore, specific posology recommendations for these patients cannot be made.
Method of administration
Established cytotoxic chemotherapy
Filgrastim may be administered as a daily subcutaneous injection or alternatively as a daily intravenous infusion over 30 minutes. For further instructions on dilution with glucose 50 mg/ml (5%) solution prior to infusion see section 6.6. The subcutaneous route is preferred in most cases. There is some evidence from a study of single dose administration that intravenous dosing may shorten the duration of effect. The clinical relevance of this finding to multiple dose administration is not clear. The choice of route should depend on the individual clinical circumstance. In randomised clinical studies, a subcutaneous dose of 23 MU/m2/day (230 μg/m2/day) or rather 0.4 - 0.84 MU/kg/day (4 - 8.4 μg/kg/day) was used.
Patients treated with myeloablative therapy followed by bone marrow transplantation
Filgrastim is administered as an intravenous short-term infusion over 30 minutes or as a subcutaneous or intravenous continuous infusion over 24 hours, in each case after dilution in 20 ml of glucose 50 mg/ml (5%) solution. For further instructions on dilution with glucose 50 mg/ml (5%) solution prior to infusion see section 6.6.
Mobilisation of PBPC
Subcutaneous injection.
For the mobilisation of PBPC in patients undergoing myelosuppressive or myeloablative therapy followed by autologous PBPC transplantation the recommended dose of filgrastim may also be administered as a 24 hour subcutaneous continuous infusion. For infusions filgrastim should be diluted in 20 ml of glucose 50 mg/ml (5%) solution. For further instructions on dilution with glucose 50 mg/ml (5%) solution prior to infusion see section 6.6.
SCN/HIV infection
Subcutaneous injection.
4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients.
4.4 Special Warnings And Precautions For Use
Special warnings
Filgrastim should not be used to increase the dose of cytotoxic chemotherapy beyond established posology regimens (see below).
Filgrastim should not be administered to patients with severe congenital neutropenia (Kostmann's syndrome) with abnormal cytogenetics (see below).
Established cytotoxic chemotherapy
Malignant cell growth
Since investigations showed that G-CSF can promote growth of myeloid cells in vitro the following warnings should be considered.
The safety and efficacy of filgrastim administration in patients with myelodysplastic syndrome, or chronic myelogenous leukaemia have not been established. Therefore filgrastim is not indicated for use in these conditions. Particular care should be taken to distinguish the diagnosis of blast transformation of chronic myeloid leukaemia from acute myeloid leukaemia.
In view of limited safety and efficacy data in patients with secondary AML, filgrastim should be administered with caution.
The safety and efficacy of filgrastim administration in de novo AML patients aged < 55 years with good cytogenetics [t(8;21), t(15;17), and inv(16)] have not been established.
Leucocytosis
White blood cell counts of 100 x 109/l or greater have been observed in less than 5% of patients receiving filgrastim at doses above 0.3 MU/kg/day (3 μg/kg/day). No undesirable effects directly attributable to this degree of leucocytosis have been reported. However, in view of the potential risks associated with severe leucocytosis, a white blood cell count should be performed at regular intervals during filgrastim therapy. If leukocyte counts exceed 50 x 109/l after the expected nadir, filgrastim should be discontinued immediately. However, during the period of administration of filgrastim for PBPC mobilisation, it should be discontinued or its dose should be reduced if the leukocyte counts rise to > 70 x 109/l.
Risks associated with increased doses of chemotherapy
Special caution should be used when treating patients with high-dose chemotherapy because improved tumour outcome has not been demonstrated and intensified doses of chemotherapeutic agents may lead to increased toxicities including cardiac, pulmonary, neurologic, and dermatologic effects (please refer to the Summary of Product Characteristics of the specific chemotherapy agents used).
Treatment with filgrastim alone does not preclude thrombocytopenia and anaemia due to myelosuppressive chemotherapy. Because of the potential of receiving higher doses of chemotherapy (e.g. full doses on the prescribed schedule) the patient may be at greater risk of thrombocytopenia and anaemia. Regular monitoring of platelet count and haematocrit is recommended. Special care should be taken when administering single or combination chemotherapeutic agents which are known to cause severe thrombocytopenia.
The use of filgrastim-mobilised PBPCs has been shown to reduce the depth and duration of thrombocytopenia following myelosuppressive or myeloablative chemotherapy.
Other special precautions
The effects of filgrastim in patients with substantially reduced myeloid progenitors have not been studied. Filgrastim acts primarily on neutrophil precursors to exert its effect in elevating neutrophil counts. Therefore, in patients with reduced precursors, neutrophil response may be diminished (such as those treated with extensive radiotherapy or chemotherapy, or those with bone marrow infiltration by tumour).
There have been reports of Graft versus Host Disease (GvHD) and fatalities in patients receiving G-CSF after allogeneic bone marrow transplantation (see section 5.1).
Mobilisation of PBPC
Prior exposure to cytotoxic agents
Patients who have undergone very extensive prior myelosuppressive therapy, followed by administration of filgrastim for mobilisation of PBPCs, may not show sufficient mobilisation of these blood cells to achieve the recommended minimum yield (6 CD34+ cells/kg) or acceleration of platelet recovery to the same degree.
Some cytotoxic agents exhibit particular toxicities to the haematopoietic progenitor pool and may adversely affect progenitor mobilisation. Agents such as melphalan, carmustine (BCNU) and carboplatin, when administered over prolonged periods prior to attempts at progenitor mobilisation may reduce progenitor yield. However, the administration of melphalan, carboplatin or BCNU together with filgrastim has been shown to be effective for progenitor mobilisation. When a PBPC transplantation is envisaged it is advisable to plan the stem cell mobilisation procedure early in the treatment course of the patient. Particular attention should be paid to the number of progenitors mobilised in such patients before the administration of high-dose chemotherapy. If yields are inadequate, as measured by the criteria above, alternative forms of treatment not requiring progenitor support should be considered.
Assessment of progenitor cell yields
In assessing the number of progenitor cells harvested in patients treated with filgrastim, particular attention should be paid to the method of quantitation. The results of flow cytometric analysis of CD34+ cell numbers vary depending on the precise methodology used and therefore, recommendations of numbers based on studies in other laboratories need to be interpreted with caution.
Statistical analysis of the relationship between the number of CD34+ cells re-infused and the rate of platelet recovery after high-dose chemotherapy indicates a complex but continuous relationship. The recommendation of a minimum yield of 6 CD34+ cells/kg is based on published experience resulting in adequate haematologic reconstitution. Yields in excess of this minimum yield appear to correlate with more rapid recovery, those below with slower recovery.
Normal donors prior to allogeneic PBPC transplantation
Mobilisation of PBPC does not provide a direct clinical benefit to normal donors and should only be considered for the purposes of allogeneic stem cell transplantation.
PBPC mobilisation should be considered only in donors who meet normal clinical and laboratory eligibility criteria for stem cell donation with special attention to haematological values and infectious disease.
The safety and efficacy of filgrastim have not been assessed in normal donors < 16 years or > 60 years.
Transient thrombocytopenia (platelets < 100 x 109/l) following filgrastim administration and leukapheresis was observed in 35% of subjects studied. Among these, two cases of platelets < 50 x 109/l were reported and attributed to the leukapheresis procedure. If more than one leukapheresis is required, particular attention should be paid to donors with platelets < 100 x 109/l prior to leukapheresis; in general apheresis should not be performed if platelets < 75 x 109/l.
Leukapheresis should not be performed in donors who are anticoagulated or who have known defects in haemostasis.
Filgrastim administration should be discontinued or its posology should be reduced if the leukocyte counts rise to > 70 x 109/l.
Donors who receive G-CSFs for PBPC mobilisation should be monitored until haematological indices return to normal.
Transient cytogenetic modifications have been observed in normal donors following G-CSF use. The significance of these changes is unknown.
Long-term safety follow-up of donors is ongoing. Nevertheless, a risk of promotion of a malignant myeloid clone can not be excluded. It is recommended that the apheresis centre perform a systematic record and tracking of the stem cell donors for at least 10 years to ensure monitoring of long-term safety.
Common but generally asymptomatic cases of splenomegaly and very rare cases of splenic rupture have been reported in healthy donors and patients following administration of G-CSFs. Some cases of splenic rupture were fatal. Therefore, spleen size should be carefully monitored (e.g. clinical examination, ultrasound). A diagnosis of splenic rupture should be considered in donors and/or patients reporting left upper abdominal pain or shoulder tip pain.
In normal donors, pulmonary adverse events (haemoptysis, pulmonary haemorrhage, pulmonary infiltrates, dyspnoea and hypoxia) have been reported very rarely in post marketing experience. In case of suspected or confirmed pulmonary adverse events, discontinuation of treatment with filgrastim should be considered and appropriate medical care given.
Recipients of allogeneic PBPCs mobilised with filgrastim
Current data indicate that immunological interactions between the allogeneic PBPC graft and the recipient may be associated with an increased risk of acute and chronic GvHD when compared with bone marrow transplantation.
SCN
Blood cell counts
Platelet counts should be monitored closely, especially during the first few weeks of filgrastim therapy. Consideration should be given to intermittent cessation or decreasing the dose of filgrastim in patients who develop thrombocytopenia, i.e. platelets consistently < 100,000/mm3.
Other blood cell changes occur, including anaemia and transient increases in myeloid progenitors, which require close monitoring of cell counts.
Transformation to leukaemia or myelodysplastic syndrome
Special care should be taken in the diagnosis of SCNs to distinguish them from other haematopoietic disorders such as aplastic anaemia, myelodysplasia, and myeloid leukaemia. Complete blood cell counts with differential and platelet counts, and an evaluation of bone marrow morphology and karyotype should be performed prior to treatment.
There was a low frequency (approximately 3%) of myelodysplastic syndromes (MDS) or leukaemia in clinical study patients with SCN treated with filgrastim. This observation has only been made in patients with congenital neutropenia. MDS and leukaemias are natural complications of the disease and are of uncertain relation to filgrastim therapy. A subset of approximately 12% of patients who had normal cytogenetic evaluations at baseline were subsequently found to have abnormalities, including monosomy 7, on routine repeat evaluation. If patients with SCN develop abnormal cytogenetics, the risks and benefits of continuing filgrastim should be carefully weighed; Filgrastim should be discontinued if MDS or leukaemia occurs. It is currently unclear whether long-term treatment of patients with SCN will predispose patients to cytogenetic abnormalities, MDS or leukaemic transformation. It is recommended to perform morphologic and cytogenetic bone marrow examinations in patients at regular intervals (approximately every 12 months).
Other special precautions
Causes of transient neutropenia, such as viral infections should be excluded.
Splenic enlargement is a direct effect of treatment with filgrastim. 31% of patients in studies were documented as having palpable splenomegaly. Increases in volume, measured radiographically, occurred early during Filgrastim therapy and tended to plateau. Dose reductions were noted to slow or stop the progression of splenic enlargement, and in 3% of patients a splenectomy was required. Spleen size should be evaluated regularly. Abdominal palpation should be sufficient to detect abnormal increases in splenic volume.
Haematuria/proteinuria occurred in a small number of patients. Regular urine analyses should be performed to monitor this event.
The safety and efficacy in neonates and patients with autoimmune neutropenia have not been established.
HIV infection
Blood cell counts
ANC should be monitored closely, especially during the first few weeks of filgrastim therapy. Some patients may respond very rapidly and with a considerable increase in neutrophil count to the initial dose of filgrastim. It is recommended that the ANC is measured daily for the first 2 - 3 days of filgrastim administration. Thereafter, it is recommended that the ANC is measured at least twice per week for the first 2 weeks and subsequently once per week or once every other week during maintenance therapy. During intermittent dosing with 30 MU/day (300 μg/day) of filgrastim, there can be wide fluctuations in the patient's ANC over time. In order to determine a patient's trough or nadir ANC, it is recommended that blood samples are taken for ANC measurement immediately prior to any scheduled dosing with filgrastim.
Risk associated with increased doses of myelosuppressive medicinal products
Treatment with filgrastim alone does not preclude thrombocytopenia and anaemia due to myelosuppressive treatments. As a result of the potential to receive higher doses or a greater number of these medicinal products with filgrastim therapy, the patient may be at higher risk of developing thrombocytopenia and anaemia. Regular monitoring of blood counts is recommended (see above).
Infections and malignancies causing myelosuppression
Neutropenia may be due to bone marrow-infiltrating opportunistic infections such as Mycobacterium avium complex or malignancies such as lymphoma. In patients with known bone marrow-infiltrating infections or malignancy, consider appropriate therapy for treatment of the underlying condition in addition to administration of filgrastim for treatment of neutropenia. The effects of filgrastim on neutropenia due to bone marrow-infiltrating infection or malignancy have not been well established.
Other special precautions
Rare pulmonary adverse reactions, in particular interstitial pneumonia, have been reported after G-CSF administration (see section 4.8). Patients with a recent history of pulmonary infiltrates or pneumonia may be at higher risk. The onset of pulmonary signs, such as cough, fever and dyspnoea in association with radiological signs of pulmonary infiltrates and deterioration in pulmonary function may be preliminary signs of Adult Respiratory Distress Syndrome (ARDS). Filgrastim should be discontinued and appropriate treatment given in these cases.
Monitoring of bone density may be indicated in patients with underlying osteoporotic bone diseases who undergo continuous therapy with filgrastim for more than 6 months.
Sickle cells crises, in some cases fatal, have been reported with the use of filgrastim in subjects with sickle cell disease. Physicians should exercise caution when considering the use of filgrastim in patients with sickle cell disease, and only after careful evaluation of the potential risks and benefits.
Increased haematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone-imaging findings. This should be considered when interpreting bone imaging results.
Excipients
Zarzio contains sorbitol. Patients with rare hereditary problems of fructose intolerance should not use this medicinal product.
In order to improve the traceability of granulocyte-colony stimulating factors (G-CSFs), the trade name of the administered product should be clearly recorded in the patient file.
4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction
The safety and efficacy of filgrastim given on the same day as myelosuppressive cytotoxic chemotherapy have not been definitively established. In view of the sensitivity of rapidly dividing myeloid cells to myelosuppressive cytotoxic chemotherapy, the use of filgrastim is not recommended in the period from 24 hours before to 24 hours after chemotherapy. Preliminary evidence from a small number of patients treated concomitantly with filgrastim and 5-fluorouracil indicates that the severity of neutropenia may be exacerbated.
Possible interactions with other haematopoietic growth factors and cytokines have not yet been investigated in clinical studies.
Since lithium promotes the release of neutrophils, lithium is likely to potentiate the effect of filgrastim. Although this interaction has not been formally investigated, there is no evidence that such an interaction is harmful.
4.6 Pregnancy And Lactation
There are no adequate data from the use of filgrastim in pregnant women. There are reports in the literature where the transplacental passage of filgrastim in pregnant women has been demonstrated. There is no evidence from studies in rats and rabbits that filgrastim is teratogenic. An increased incidence of embryo-loss has been observed in rabbits, but no malformation has been seen.
In pregnancy, the possible risk of filgrastim use to the foetus must be weighed against the expected therapeutic benefit.
It is not known whether filgrastim is excreted in human milk, therefore it is not recommended for use in breast-feeding women.
4.7 Effects On Ability To Drive And Use Machines
Filgrastim has no influence on the ability to drive and use machines.
4.8 Undesirable Effects
The most commonly reported adverse reactions to filgrastim are mild to moderate musculoskeletal pain occurring in more than 10% of patients. Musculoskeletal pain is usually controlled with standard analgesics.
Adverse reactions listed below are classified according to frequency and system organ class. Frequency groupings are defined according to the following convention: Very common (
Table 1. Adverse reactions in clinical trials in cancer patients
Immune system disorders
|
|
|
|
Very rare:
|
Allergic-type reactions*, including anaphylaxis, skin rash, urticaria, angioedema, dyspnoea and hypotension
|
Vascular disorders
|
|
|
|
Uncommon:
|
Hypotension (transient)
|
|
Rare:
|
Vascular disorders* including venoocclusive disease and fluid volume disturbances
|
Respiratory, thoracic and mediastinal disorders
|
|
|
|
Very rare:
|
Pulmonary oedema*, interstitial pneumonia*, pulmonary infiltrates*
|
Skin and subcutaneous tissue disorders
|
|
|
|
Very rare:
|
Sweet's Syndrome*, cutaneous vasculitis
|
Musculoskeletal, connective tissue and bone disorders
|
|
|
|
Very common:
|
Musculoskeletal pain (mild or moderate)
|
|
Common:
|
Musculoskeletal pain (severe)
|
|
Very rare:
|
Rheumatoid arthritis exacerbation
|
Renal and urinary disorders
|
|
|
|
Very rare:
|
Micturition disorders (predominantly dysuria)
|
Investigations
|
|
|
|
Very common:
|
Blood alkaline phosphatase, blood lactate dehydrogenase (LDH), gamma-glutamyltransferase (GGT) and blood uric acid increased (reversible, dose-dependent, mild or moderate)
|
* see below
Table 2. Adverse reactions in clinical trials in normal donors undergoing PBPC mobilisation
Immune system disorders
|
|
|
|
Uncommon:
|
Severe allergic reaction: anaphylaxis, angioedema, urticaria, rash
|
Blood and the lymphatic system disorders
|
|
|
|
Very common:
|
Leucocytosis (WBC > 50 x 109/l), thrombocytopenia (platelets < 100 x 109/l; transient)
|
|
Common:
|
Splenomegaly (generally asymptomatic, also in patients)
|
|
Uncommon:
|
Spleen disorder
|
|
Very rare:
|
Splenic rupture (also in patients)
|
Nervous system disorders
|
|
|
|
Very common:
|
Headache
|
Respiratory, thoracic and mediastinal disorders
|
|
|
|
Very rare:
|
Haemoptysis*, pulmonary haemorrhage*, pulmonary infiltrates*, dyspnoea*, hypoxia*
|
Musculoskeletal, connective tissue and bone disorders
|
|
|
|
Very common:
|
Musculoskeletal pain (mild to moderate, transient)
|
|
Uncommon:
|
Rheumatoid arthritis and arthritic symptoms exacerbation
|
Investigations
|
|
|
|
Common:
|
Blood alkaline phosphatase and LDH increased (transient, minor)
|
|
Uncommon:
|
Aspartate aminotransferase (AST) and blood uric acid increased (transient, minor)
|
* see below
Table 3. Adverse reactions in clinical trials in SCN patients
Blood and the lymphatic system disorders
|
|
|
|
Very common:
|
Anaemia, splenomegaly (may be progressive in a minority of cases)
|
|
Common:
|
Thrombocytopenia
|
|
Uncommon:
|
Spleen disorder
|
Nervous system disorders
|
|
|
|
Common:
|
Headache
|
Respiratory, thoracic and mediastinal disorders
|
|
|
|
Very common:
|
Epistaxis
|
Gastrointestinal disorders
|
|
|
|
Common:
|
Diarrhoea
|
Hepato-biliary disorders
|
|
|
|
Common:
|
Hepatomegaly
|
Skin and subcutaneous tissue disorders
|
|
|
|
Common:
|
Cutaneous vasculitis (during long term use), alopecia, rash
|
Musculoskeletal, connective tissue and bone disorders
|
|
|
|
Very common:
|
General musculoskeletal pain, bone pain
|
|
Common:
|
Osteoporosis, arthralgia
|
Renal and urinary disorders
|
|
|
|
Uncommon:
|
Haematuria, proteinuria
|
General disorders and administration site conditions
|
|
|
|
Common:
|
Injection site pain
|
Investigations
|
|
|
|
Very common:
|
Blood alkaline phosphatase, LDH and blood uric acid increased (transient), blood glucose decreased (transient, moderate)
|
Table 4. Adverse reactions in clinical trials in HIV Patients
Blood and lymphatic system disorders
|
|
|
|
Common:
|
|
